

March 27, 2019



## Rexahn Announces Multiple Presentations at the 2019 American Association for Cancer Research Annual Meeting

ROCKVILLE, M.D., March 27, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced that it will present four scientific posters at the 2019 American Association for Cancer Research (AACR) Annual Meeting, which will be held from March 29 – April 3, 2019 in Atlanta, Georgia.

Details of the poster presentations are as follows:

**Title:** Phenotyping pancreatic cancer CTCs as biomarkers for RX-3117 clinical trial  
**Session Date and Time:** Sunday, March 31, 2019 1:00 PM - 5:00 PM  
**Session Title:** Circulating and Cell-free Biomarkers for Diagnosis and Monitoring of Cancer 1  
**Location:** Georgia World Conference Center, Exhibit Hall B, Poster Section 17  
**Abstract Number:** 428  
**Abstract Link:** <https://www.abstractsonline.com/pp8/#!/6812/presentation/7993>

**Title:** RX-5902 exhibits direct and immunomodulatory anti-tumor activities in melanoma PDX models  
**Session Date and Time:** Tuesday, April 2, 2019 1:00 PM - 5:00 PM  
**Session Title:** Novel Immunomodulatory Agents 2  
**Location:** Georgia World Conference Center, Exhibit Hall B, Poster Section 25  
**Abstract Number:** 4127  
**Abstract Link:** <https://www.abstractsonline.com/pp8/#!/6812/presentation/3309>

**Title:** The anticancer effects of RX-5902 result from inhibition of phosphorylated p68-mediated  $\beta$ -catenin nuclear translocation  
**Session Date and Time:** Monday, April 1, 2019 8:00 AM - 12:00 PM  
**Session Title:** Novel Targets and Pathways  
**Location:** Georgia World Conference Center, Exhibit Hall B, Poster Section 14  
**Abstract Number:** 1298  
**Abstract Link:** <https://www.abstractsonline.com/pp8/#!/6812/presentation/5514>

**Title:** Unusual mechanism of resistance to the novel cytidine analog fluorocyclopentenylcytosine (RX-3117)  
**Session Date and Time:** Monday, April 1, 2019 8:00 AM - 12:00 PM  
**Session Title:** Drug Resistance 2  
**Location:** Georgia World Conference Center, Exhibit Hall B  
**Abstract Number:** 1267  
**Abstract Link:** <https://www.abstractsonline.com/pp8/#!/6812/presentation/1631>

Copies of the abstracts are available and can be viewed online through the AACR website at [www.aacr.org](http://www.aacr.org). Once presented, copies of the posters will be available on the company's website at <https://rexahn.com/cms/media-center/publication/posters/>.

### About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals Inc. (NYSE American: RNN) is a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat. The Company's mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn's product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. Preclinical studies show that several of Rexahn's product candidates may be effective against multiple types of cancer, including drug resistant cancers, and difficult-to-treat cancers and others may augment the effectiveness of current FDA-approved cancer treatments. The Company has

two oncology product candidates, RX-3117 and RX-5902, in Phase 2 clinical development and additional compounds in preclinical development, including RX-0301. For more information about the Company and its oncology programs, please visit [www.rexahn.com](http://www.rexahn.com).

### **Safe Harbor**

To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Rexahn's plans, objectives, expectations and intentions with respect to cash flow requirements, future operations and products, enrollments in clinical trials, the path of clinical trials and development activities, expected results of the Company's planned cost reductions, and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," and other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Rexahn's actual results to be materially different than those expressed in or implied by Rexahn's forward-looking statements. For Rexahn, particular uncertainties and risks include, among others, understandings and beliefs regarding the role of certain biological mechanisms and processes in cancer; drug candidates being in early stages of development, including clinical development; the ability to initially develop drug candidates for orphan indications to reduce the time-to-market and take advantage of certain incentives provided by the U.S. Food and Drug Administration; the ability to transition from our initial focus on developing drug candidates for orphan indications to candidates for more highly prevalent indications; the availability and access to capital; and the expected timing of results from our clinical trials. More detailed information on these and additional factors that could affect Rexahn's actual results are described in Rexahn's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K. All forward-looking statements in this news release speak only as of the date of this news release. Rexahn undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

### **Investor Contact:**

[ir@rexahn.com](mailto:ir@rexahn.com)



Source: Rexahn Pharmaceuticals